AI
RLMD icon

AdvisorShares Investments’s Relmada Therapeutics RLMD Stock Holding History

AdvisorShares Investments’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.06M Sell
295,872
-23,638
-7% -$112K 0.38% 42
2025
Q4 		$1.54M Sell
319,510
-83,978
-21% -$281K 0.26% 53
2025
Q3 		$811K Buy
403,488
+6,974
+2% +$6.69K 0.13% 88
2025
Q2 		$238K Buy
396,514
+120,000
+43% +$61.6K 0.04% 215
2025
Q1 		$75.7K Buy
276,514
+66,446
+32% +$22K 0.01% 256
2024
Q4 		$109K Buy
210,068
+141,540
+207% +$345K 0.02% 245
2024
Q3 		$222K Sell
68,528
-21,500
-24% -$69.6K 0.04% 211
2024
Q2 		$276K Buy
90,028
+19,975
+29% +$72.3K 0.05% 207
2024
Q1 		$326K Sell
70,053
-4,613
-6% -$22.2K 0.05% 202
2023
Q4 		$309K Sell
74,666
-38,242
-34% -$113K 0.07% 204
2023
Q3 		$339K Buy
112,908
+10
+0% +$30 0.09% 167
2023
Q2 		$278K Buy
112,898
+8,758
+8% +$24.2K 0.08% 185
2023
Q1 		$235K Buy
104,140
+22,778
+28% +$78.5K 0.07% 180
2022
Q4 		$284K Buy
81,362
+70,904
+678% +$623K 0.08% 197
2022
Q3 		$387K Buy
+10,458
New +$290K 0.1% 185

Other funds holding RLMD

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
SSC
Spruce Street Capital New York $416M AUM
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

AdvisorShares Investments's RLMD Position: Q1 2026 in Review

AdvisorShares Investments reduced its Relmada Therapeutics (RLMD) stake by 7.4% in Q1 2026, selling an estimated $112K and leaving 295,872 shares worth $2.06M. The position accounts for 0.38% of the portfolio, ranked #42.

AdvisorShares Investments first reported a position in RLMD in Q3 2022 and has held it in 15 quarters since. 103 funds tracked by Wall St. Rank hold RLMD as of Q1 2026.

  • AdvisorShares Investments held 295,872 shares of Relmada Therapeutics worth $2.06M as of Q1 2026.
  • AdvisorShares Investments sold 23,638 Relmada Therapeutics shares in Q1 2026, an estimated $112K.
  • Relmada Therapeutics made up 0.38% of AdvisorShares Investments's portfolio in Q1 2026, its #42 holding.
  • AdvisorShares Investments first reported a position in Relmada Therapeutics in Q3 2022 and has held it in 15 quarters since.
  • 103 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2026.

Based on AdvisorShares Investments's 13F filing for Q1 2026, filed 28 Apr 2026.